The genetic basis of response to checkpoint inhibitors Why do some patients respond and how can we predict who will?

被引：0
|
作者：
Kotoula, Vassiliki [1 ]
机构：
[1] Aristotle Univ Thessaloniki, Dept Pathol, Sch Med, Thessaloniki, Greece
来源：
MEDICINE | 2019年 / 98卷 / 26期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 20 条
  • [1] How confidently can we predict response in patients with MDD?
    Gorwood, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S631 - S631
  • [2] How can We Predict Efficacy of rFVIIa in Hemophilia Patients with Inhibitors?
    Dargaud, Yesim
    Bordet, Jean C.
    Huchon, Chantal
    Negrier, Claude
    BLOOD, 2009, 114 (22) : 1354 - 1354
  • [3] WHY DO PATIENTS DISCONTINUE FERTILITY TREATMENT PREMATURELY AND HOW DO WE PREDICT DISCONTINUATION BEHAVIOUR?
    Gameiro, S.
    Verhaak, C. M.
    Peronace, L.
    Boivin, J.
    INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2014, 21 : S207 - S207
  • [4] Cost-effective use of interferon-alpha in hepatitis C - How can we predict who will respond?
    Colombo, M
    BIODRUGS, 1997, 7 (03) : 198 - 202
  • [5] Aerosol Therapy in Asthma-Why We Are Failing Our Patients and How We Can Do Better
    Morton, Robert W.
    Elphick, Heather E.
    Craven, Vanessa
    Shields, Michael D.
    Kennedy, Lesley
    FRONTIERS IN PEDIATRICS, 2020, 8
  • [6] Patients Who Do Not Respond to the "Usual" Dose: Why Terry Fell Off the Dose-Response Curve
    Preskorn, Sheldon H.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2009, 15 (06) : 460 - 466
  • [7] Botulinum Toxin for the Management of Cervical Dystonia and Why Patients Discontinue Treatment: How Can We Do Better?
    Slawek, Jaroslaw
    TOXICON, 2024, 237 : 81 - 82
  • [8] Is preimplantation genetic testing for aneuploidy (PGT-A) getting better? How can we know and how do we counsel our patients?
    Paulson, Richard J.
    F&S REPORTS, 2023, 4 (04): : 329 - 330
  • [9] Biochemical monitoring in patients who start with renin-angiotensin system inhibitors: how well do we monitor?
    Bootsma, J.
    van Herwaarden, M.
    Sa'ado, F.
    Verbeek, A.
    Fussenich, P.
    de Smet, P.
    Rikkert, M. Olde
    Kramers, C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (06) : 706 - 706
  • [10] Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors?
    Sutcliffe, Megan
    Radley, Gemma
    Barton, Anne
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (04) : 389 - 396
12